Systemic Effects of Orally Administered Interferons and Interleukin-2
- 1 August 1999
- journal article
- research article
- Published by Mary Ann Liebert Inc in Journal of Interferon & Cytokine Research
- Vol. 19 (8) , 829-839
- https://doi.org/10.1089/107999099313334
Abstract
Orally administered interferons (IFN-alpha, IFN-beta, and IFN-gamma) have been shown to exert a number of systemic effects. Orally administered IFNs exert dose-dependent suppressive effects on the peripheral white blood cell (WBC) count. The suppression of the peripheral WBC count is mediated by a suppression of the function of the bone marrow, as measured in an in vitro bone marrow colony-forming assay. The peripheral WBC and bone marrow suppressive effects of orally administered IFNs are at least as potent as those occurring with parenterally administered IFNs. However, the mechanism by which orally administered IFNs exert these peripheral WBC suppressive and bone marrow suppressive effects differs significantly from that of parenterally administered IFNs: orally administered IFN is not detectable in the serum, the effect of orally administered IFN is not blocked by circulating antibody, the effect of orally administered IFN can be adoptively transferred by injection with peripheral white blood cells from donor mice, and the effect of orally administered IFN develops more slowly than that of parenterally administered interferon. Orally administered IFN-alpha employed alone and in synergistic combination with intraperitoneally administered IFN-gamma can exert an antitumor effect. Finally, orally administered interleukin-2 can exert a suppressive effect on both the peripheral white blood cell count and on the bone marrow. These observations suggest that the oral route may be an effective and novel mechanism for the efficacious administration of IFNs and other lymphokines/cytokines.Keywords
This publication has 21 references indexed in Scilit:
- Oromucosal Interferon Therapy: Marked Antiviral and Antitumor ActivityJournal of Interferon & Cytokine Research, 1999
- Orally Administered IFN-α Acts Alone and in Synergistic Combination with Intraperitoneally Administered IFN-γ to Exert an Antitumor Effect Against B16 Melanoma in MiceJournal of Interferon & Cytokine Research, 1998
- Low-Dose Oral Type I Interferons Reduce Early Virus Replication of Murine CytomegalovirusIn VivoJournal of Interferon & Cytokine Research, 1997
- Intranasal Administration of IFN-α/β Inhibits the Development of Visceral Tumor MetastasesJournal of Interferon & Cytokine Research, 1997
- Oral application of cytokinesBiotherapy, 1996
- Intranasally administered alpha/beta interferon prevents extension of mouse hepatitis virus, strain JHM, into the brains of BALB/cByJ miceAntiviral Research, 1987
- Quantitation ofIn VivoPotentiation Resulting from Combined Interferon Therapy: Antitumor Effect Against B-16 Melanoma in MiceJournal of Interferon Research, 1986
- Prevention of Natural Colds by Contact Prophylaxis with Intranasal Alpha2-InterferonNew England Journal of Medicine, 1986
- Requirement for IFN Gamma in Potentiation of Interferon's Antiviral and Anticellular Activities: Identity of Mouse and Human SystemsJournal of Interferon Research, 1984
- Interferon Administered Orally: Protection of Neonatal Mice from Lethal Virus ChallengeScience, 1972